Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
Opfolda
Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid ?- glucosidase [GAA] deficiency).
View on EMAZavesca
Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.
View on EMA